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Abstract
Rodent pancreatic b-cells that naturally lack hypoglycemia/hypoxia inducible mitochondrial protein 1 (HIMP1) are
susceptible to hypoglycemia and hypoxia influences. A linkage between the hypoglycemia/hypoxia susceptibility and the
lack of HIMP1 is suggested in a recent study using transformed b-cells lines. To further illuminate this linkage, we applied
mouse insulin 1 gene promoter (MIP) to control HIMP1-a isoform cDNA and have generated three lines (L1 to L3) of
heterozygous HIMP1 transgenic (Tg) mice by breeding of three founders with C57BL/6J mice. In HIMP1-Tg mice/islets, we
performed quantitative polymerase chain reaction (PCR), immunoblot, histology, and physiology studies to investigate
HIMP1 overexpression and its link to b-cell function/survival and body glucose homeostasis. We found that the HIMP1 level
increased steadily in b-cells of L1 to L3 heterozygous HIMP1-Tg mice. HIMP1 overexpression at relatively lower levels in L1
heterozygotes results in a negligible decline in blood glucose concentrations and an insignificant elevation in blood insulin
levels, while HIMP1 overexpression at higher levels are toxic, causing hyperglycemia in L2/3 heterozygotes. Follow-up
studies in 5–30-week-old L1 heterozygous mice/islets found that HIMP1 overexpression at relatively lower levels in b-cells
has enhanced basal insulin biosynthesis, basal insulin secretion, and tolerances to low oxygen/glucose influences. The
findings enforced the linkage between the hypoglycemia/hypoxia susceptibility and the lack of HIMP1 in b-cells, and show a
potential value of HIMP1 overexpression at relatively lower levels in modulating b-cell function and survival.
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Introduction
Pancreatic b-cell failure in diabetes is characterized primarily by
progressive loss of insulin production and b-cell mass. b-cell failure
has been attributed to autoimmune assault in type 1 diabetes and
to glucolipotoxicity, amyloid deposition, insulin resistance, and
endoplasmic reticulum (ER) and/or oxidative stress in type 2
diabetes [1–7]. However, the intrinsic mechanisms underlying b-
cell susceptibility to stress and damage remains largely unclear.
Are b-cells overwhelmed by such stress and its associated toxic
byproducts, such as reactive oxygen species (ROS), or does the
attenuation of beneficial genes and/or trigger of harmful genes
prove detrimental to some inherent property specific to cell type?
Data exist to support both views, but b-cell dysfunction and
damage resulting from various stress insults, such as from
hypoglycemia/hypoxia [8,9] and chronic hyperglycemic and
hyperlipidemic conditions [7,10–12], in addition to influences by
genetic variations support the second view.
For example, the lack of regular blood flows in early hours of
islet transplantation leads to insufficient supplies of oxygen and
nutrients (e.g., glucose) within implanted islets. This hypoglyce-
mia/hypoxia influence is implicated in b-cell damages within
implanted islets, which limits a long-term success of this technique
for patients with type 1 diabetes in clinical practice [8,13–16].
Likewise, as b-cells mature to produce insulin, they become
sensitive to cytokine insult [17]. Insulin is the most abundant and
unique protein manufactured in b-cells. Proinsulin, the predom-
inant form of insulin precursor in the ER, preserves a low relative
folding rate, and bears the greatest burden in the protein folding of
b-cells. Thus, it maintains a homeostatic balance of natively and
plentiful non-natively folded states (i.e., proinsulin homeostasis,
PIHO) in b-cells as a result of the integration of maturation and
disposal processes [18]. The low relative folding rate and plentiful
insulin precursor manufactured in b-cells make PIHO susceptible
to genetic and environmental influences, and PIHO disorder has
been critically linked to defects in b-cells in diabetes [18].
Moreover, low expression levels of genes protective against
oxidative stress, such as catalase, in the b-cells is proposed to
contribute to b-cell stress susceptibilities [19,20]. Recently, in our
efforts to identify important differences in gene expression in
pancreatic a- versus b-cells, a gene termed HIMP1 (hypoglyce-
mia/hypoxia inducible mitochondrial protein) and its protein
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known as hypoxia induced gene 1 (Hig1), is a main characterized
member of a gene family conserved throughout evolution, with
members in a-proteobacteria and diverse eukaryotic taxa such as
fish and humans [21,22]. HIMP1 is also called Higd-1a [23]. In
mice, its two alternatively spliced products (HIMP1-a and HIMP1-
b) each form a transmembrane loop, having an Noutside–Coutside
orientation and are expressed highly in the mitochondrial inner
membrane in several tissues including heart and pancreatic a-cells,
but are not or are only lowly expressed in b-cells [21]. Ectopic
expression of HIMP1 in MIN6 b-cells protects the cells from
apoptosis induced by hypoglycemia and hypoxia insults and
prolongs their survival, suggesting an important role for HIMP1 in
stress protective programs in mitochondria [21]. A recently
reported study has shown that the anti-apoptotic effect of HIMP1
results from inhibiting cytochrome C release and reducing caspase
activities in mouse macrophage cell lines [23].
To further understand the intrinsic mechanisms for hypoglyce-
mia/hypoxia susceptibilities of b-cells, we produced novel
transgenic (Tg) mice with HIMP1-a overexpression by the control
of mouse insulin 1 gene promoter (MIP, ,8.3 kb in length). The
application of MIP allows ectopic HIMP1-a expression only within
pancreatic b-cells in body. Results of our characterizations on
HIMP1-Tg mice show that b-cells with relative low levels of
HIMP1 have enhanced basal insulin production and tolerances to
hypoxia/hypoglycemia. The findings validate the linkage between
the hypoglycemia/hypoxia susceptibility and the lack of HIMP1 in
mouse primary b-cells, and show a potential value of HIMP1
overexpression at relative lower levels in modulating b-cell
function and survival.
Results
Levels of HIMP1 overexpression in b-cells determined
phenotypes in HIMP1-Tg mice
Three transgenic founders were identified by amplification of a
DNA fragment (364 bp) specifically from the MIP-HIMP1
expression cassette (diagrammed in Fig. 1A) rather than natural
HIMP1 gene in the genome of mouse as described in the Materials
and Methods. Heterozygous HIMP1 transgenic mice of 3 lines
denoted as ‘HIMP1-Tg L1, L2 and L3’ were produced by
breeding of transgenic founders with C57BL/6J mice. Levels of
the MIP-HIMP1 expression cassette DNA that was integrated in
the genome of HIMP1-Tg mice were examined by using genomic
DNAs of tail tissues as templates and the quantitative PCR
approach described previously [24]. Results showed a steady
increase of the MIP-HIMP1 expression cassette DNA level from
L1 to L3 line heterozygotes. But no signal was evident in wild-type
littermates because these mice do not carry the MIP-HIMP1
expression cassette DNA in their genome (Fig. 1B). Phenotype
characterizations (detailed later) exposed a negligible decline in the
blood glucose level of 5–30-week-old L1 heterozygous mice, while
hyperglycemia appeared in 5-week-old L2/3 heterozygous mice
with no evident obesity or significant sex differences. Genetic/
phenotype traits of HIMP1-Tg mice followed the mode of
Mendelian inheritance. The differences in the level of the MIP-
HIMP1 expression cassette DNA (Fig. 1B) may result from
variations in the number of MIP-HIMP1 DNA integrated in
genome, which may potentially be responsible for discrepancies in
the phenotype of HIMP1-Tg mice between 3 lines.
The level of HIMP1 protein in the pancreatic tissues of L1 to L3
heterozygotes increased steadily than did in wild-type littermate
controls (Fig. 1C; control, 100610%; L1, 480621%; L2,
624613%; L3, 1050660%; n=5, P,0.01). This result further
supports that there is a linkage between the HIMP1 overexpres-
sion levels and the phenotype variations in HIMP1-Tg mice of 3
lines. To prove this linkage, we produced L1 homozygotes by
breeding of L1 heterozygote siblings. As expected, hyperglycemia
(11.660.6 mmol/l) developed by 5 weeks of age in L1
homozygotes, which preserved double the amount of MIP-HIMP1
DNA than did L1 heterozygote parents. The level of HIMP1
protein in the islets of L1 homozygotes versus wild-type controls
(Fig. 1D; control, 100622%; L1, 500616%; L1 homozygote,
738622%, n=5, P,0.01) is comparable to the level in L2
heterozygotes (Fig. 1C). This genetic evidence enforced the linkage
between the levels of HIMP1 overexpression and the phenotypes
in HIMP1-Tg mice.
To elucidate whether the increase of HIMP1 protein occurs
specifically in b-cells, we performed histological studies on
pancreatic sections of HIMP1-Tg mice (but excluded the L3 line
which was lost by accident). As shown in Fig. 1E, HIMP1
immunoreactivities were evident in a-cells rather than in islet b-
cells (marked with C-peptide immunoreactivities) or exocrine cells
of normal pancreatic tissues, which is consistent with our previous
observation [21]. In contrast, HIMP1 immunoreactivities were
clearly evident as well in the islet b-cells (marked with C-peptide
immunoreactivities) of HIMP1-Tg mice. Moreover, an increased
tendency in the HIMP1signals was shown in pancreatic tissues
derived from L1 to L2 heterozygotes or L1 homozygotes (Fig. 1E).
These results concluded that differences in the levels of HIMP1
overexpression in b-cells are responsible for the phenotype traits of
HIMP1-Tg mice. The studies shown below mainly are the
characterizations on consequences of HIMP1 overexpression at
relatively lower levels in L1 heterozygotes. Toxic consequences of
HIMP1 overexpression at higher levels in diabetic L1 homozy-
gotes or L2 heterozygotes will be characterized and described in
details elsewhere.
Heterozygous HIMP1-Tg-L1 mice show a negligible
decline in blood glucose levels
Under ad libitum feeding conditions, 5–30-week-old heterozy-
gous HIMP1-Tg-L1 mice showed, only slightly and insignificantly,
lower blood glucose levels (Fig. 2A and B), less body weight (Fig. 2E
and F), and higher insulin levels (Fig. 2C and D) than did wild-type
littermate mice. Moreover, no apparent alteration in these
phenotype traits was found in L1 heterozygotes during a long-
term (two years) observation. These data indicate that heterozy-
gous HIMP1-Tg-L1 mice preserve a negligibly improved glucose
metabolism. In contrast, HIMP1 overexpression at toxic higher
levels caused hyperglycemia in L1 homozygotes and L2/3
heterozygotes by 5 weeks of age (Fig. S1) as introduced early in
the Results section.
b-cells of heterozygous HIMP1-Tg-L1 mice show an
enhanced tolerance to low oxygen/glucose insults
To examine whether primary L1 b-cells enhances tolerance to
hypoxia/hypoglycemia stress as that observed in b-cell lines with
transfected HIMP1 cDNAs [21], we applied similar approaches as
reported [21] and examined the viability of islet cells derived from
L1 mice and wild-type littermates by the method of trypan blue
staining. This method can distinguish viable cells from dead cells
via apoptotic or necrotic pathways. Examination results show that,
after a 15 h incubation at the hypoxia (5% O2) or 48 h low glucose
(2.5 mmol/l) condition, the proportion of viable L1 cells increased
with a decreased proportion of dead L1 cells by comparison with
wild-type controls (Fig. 3, P,0.05, n=6). In contrast, no
significant difference was found in the viability of L1 islet cells
Effects of Ectopic HIMP1 Overexpression in b-Cells
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glucose (11 mmol/l) condition (Fig. 3). These results showed the
role of HIMP1 in protective programs of islet primary b-cells
against low oxygen/glucose insults. This is because HIMP1
overexpression is the primary genetic alteration in L1 b-cells and
no change in a- and b-cell populations (that is described in the last
paragraph of the Result section) contributes to the increased
viability of HIMP1-Tg-L1 islet cells.
Heterozygous HIMP1-Tg-L1mice show an enhanced
basal insulin secretion
To investigate the effect of HIMP1 overexpression on insulin
secretion of L1 b-cells in vivo, we performed intraperitoneal glucose
tolerance test (IPGTT) and examined basal (fasting) insulin release
and glucose-stimulated insulin secretion (GSIS) by b-cells of 5- and
8-week-old L1 heterozygotes. Results exposed no apparent defects
in GSIS or glucose tolerance in heterozygous HIMP1-Tg-L1 mice
by comparison with littermate controls (Fig. 4). A similar result was
found in 30-week-old L1 heterozygotes, and these observations
were evident as well by analyses of AUC glucose and AUC insulin
in IPGTT studies (data not shown). However, an increase in basal
insulin levels were detected in 5- and 8-week-old L1 heterozygous
mice after a 15 h fasting (Fig. 4, P,0.05; n=10). This result
indicates that HIMP1 overexpression at relatively low levels in
heterozygous HIMP1-Tg-L1 b-cells has enhanced basal insulin
secretion.
Heterozygous HIMP1-Tg-L1 islets show an enhanced
basal (pro)insulin biosynthesis
To investigate mechanisms for the enhanced basal insulin
secretion from L1 b-cells, we performed ex vivo studies on 5-week-
old heterozygous L1 islets. After a 15 h culture under the
2.5 mmol/l glucose condition, an increase occurred in the level
of secreted insulin from L1 islets compared to wild-type controls in
radioimmunoassay (RIA) studies (Fig. 5A, P,0.05, n=6), despite
that no difference appeared in the percentage of secreted insulin in
the islet insulin content (Fig. 5A, lower panel). Using immunoblot
methods described recently [18], our further examination on islet
Figure 1. The levels of MIP-HIMP1 expression cassette DNA and HIMP1 protein in pancreatic/islet tissues of HIMP1-Tg mice. (A)
Diagram of MIP-HIMP1 expression cassette. MIP, mouse insulin1 promoter, GH, a fragment of growth hormone gene. (B) The levels of MIP-HIMP1
expression cassette DNA in HIMP1-Tg mice were examined by quantitative PCR methods with
32P-labeled primers as described previously [24].
Pancreatic (C) or islet (D) HIMP1 protein levels of 5–30-week-old HIMP1-Tg mice were determined by immunoblot analysis, normalized by tubulin,
and compared with wild-type littermate controls. (E) Representative images of HIMP1 (red) and C-peptide (green) immunoreactive materials in
pancreatic tissues of 5-week-old male HIMP1-Tg and control mice. 50 mg proteins per lane in (C) and (D). Wt, wild-type littermate; L1, L1
heterozygotes; L2, L2 heterozygotes; L3, L3 heterozygotes; homoL1, L1 homozygotes. The data in (C) and (D) were shown as mean 6 SD, n=6;
**, P,0.01. Bar in (E), 100 mm.
doi:10.1371/journal.pone.0034126.g001
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and insulin content of L1 islets compared to wild-type controls
(Fig. 5B, P,0.05, n=6). Because b-cell population in L1 islets
versus size-matched control islets is unaltered (Fig. 5C), these
results together demonstrated that HIMP1 overexpression at
relatively low levels in L1 b-cells has enhanced basal (pro)insulin
biosynthesis and insulin secretion in vivo. Under the high glucose
(11 mmol/l) customary culture condition, however, no significant
difference was found in the (pro)insulin content or secreted insulin
of the two islet groups, despite the slight increase that indeed did
occur in L1 islets versus wild-type controls (Fig. S2). These findings
are consistent with observations in the in vivo IPGTT studies
(Fig. 4).
Discussion
In our efforts to develop better understanding of the
mechanisms for b-cell susceptibility to hypoxia/hypoglycemia,
we have produced 3 lines of HIMP1-Tg mice with HIMP1
overexpression specifically within b-cells in this study. Analysis of
genomic DNAs and pancreas/islet proteins uncovered a steady
increase of HIMP1 level in b-cells of L1 to L3 heterozygotes
(Figs. 1B, C and D). Intriguingly, phenotype characterizations
exposed a slight and insignificant improvement in glucose
metabolism of L1 heterozygotes that preserve relatively low levels
of HIMP1 overexpression (Figs. 1 and 2). In contrast, hypergly-
cemia developed early in 5-weeks-old L2/3 heterozygotes that
preserve relatively high levels of HIMP1 overexpression. These
observations suggest that the variation in phenotype is correlated
with the difference in the level of HIMP1 overexpression in the 3
lines of HIMP1-Tg mice. This proposition was proven by the fact
that hyperglycemia developed in L1 homozygotes that were
inherent with double amounts of MIP-HIMP1 DNAs and higher
HIMP1 overexpression levels than that in heterozygote parents
(Fig. 1D and E). These data also suggest that HIMP1
overexpression at relatively low levels in b-cells exerts somewhat
beneficial effects on b-cell function while at higher levels would
result in toxic consequences such as b-cell failure and diabetes.
Because diabetes often developed in engineered animals with
overexpression of some (even beneficial) molecules under the
Figure 2. Phenotypes of heterozygous HIMP1-Tg-L1 mice. Blood glucose (A, n=30) or insulin (C, n=10) level and body weight (E, n=30) of 5–
30-week-old L1 heterozygotes or wild-type (Wt) littermates were measured under ad libitum feeding conditions and the average values were shown
in B, D, and F. Equal numbers of male and female mice in individual groups were tested. Data were shown as mean 6 SD.
doi:10.1371/journal.pone.0034126.g002
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developed in L1 homozygotes and L2/3 heterozygotes due to toxic
higher levels of HIMP1 overexpression is comprehensible.
Additionally, HIMP-L3 mice were lost because of accidents that
happened during maintenance processes.
Our studies on dispersed L1 islet cells show that HIMP1
overexpression at relatively low levels has enhanced the viability of
b-cells and the tolerance to cell death induced by low oxygen/
glucose insults (Fig. 3). This finding and a recently reported study
in mouse macrophage cell lines [23] further validated the
suggested role of HIMP1 in protective programs of cells against
low glucose and hypoxia insults [21]. These data provide better
understanding of function(s) of HIMP1protein and its homologues.
Function(s) of these proteins as members of a novel family remains
to be established.
Our IPGTT studies found a significant increase in fasting (basal)
insulin levels of L1 heterozygous mice (Fig. 4). In line with this
result, the outcomes of ex vivo islet studies further showed that, after
a 15 h incubation at the 2.5 mmol/l glucose condition, there was
an increase in the (pro)insulin content and secreted insulin of L1
islets versus wild-type controls (Figs. 5A and B). Because b-cell
populations remained unaltered in L1 versus size-matched control
islets (Fig. 5C), these data clearly demonstrated that HIMP1
overexpression at relatively low levels in heterozygous L1 b-cells
has enhanced basal (pro)insulin biosynthesis and basal insulin
secretion.
Previously reported studies show that overexpression of some
anti-oxidative enzymes and mitochondrial proteins such as
catalase or Bcl(X)L [25,26] specifically in b-cells improved cell
survival capacity but not (pro)insulin biosynthesis. This study
shows the first clear evidence that b-cells with HIMP1 overex-
pression at relatively low levels have enhanced basal (pro)insulin
production in addition to tolerances to low oxygen or glucose
insults. This finding is quite intriguing because it indicates that
enhancements in the basal insulin synthesis and secretion can be
achieved by overexpression of only a mitochondrial inner
membrane protein in b-cells. This enhancement would be
incomparable with the increase in the basal insulin secretion
observed in type 2 diabetes with obesity [29,30]. This is because
obese and diabetes does not develop in heterozygous HIMP1-Tg-
L1 mice. Moreover, the increase in the basal insulin secretion in
type 2 diabetes with obesity is associated with a decrease in the b-
cell’s intracellular stores that cannot be offset by commensurate
free fatty acid induction of proinsulin biosynthesis [30]. In
addition, the increased basal (pro)insulin synthesis in heterozygous
L1 islets (Fig. 5B) suggests that transcriptional and/or translational
regulations for the increase may occur somehow. However, it
remains to the clarified what or how mitochondrial messages
changed as a result of HIMP1 overexpression that link to
regulations in the transcription, translation, and secretion
processes of insulin in L1 islets/b-cells. In addition, whether there
is any possible means to regulating optimal expressions of natural
HIMP1 gene in b-cells remains to be investigated. A recently
reported study showed that transcription of HIMP1 is regulated by
binding of the transcription factor HIF to the hypoxia-response
element site in the HIMP1 promoter in mouse macrophage cell
lines [23]. HIF is expressed in pancreatic b-cells as well [9,31,32],
but why the HIMP1 protein is not normally expressed in mouse
Figure 3. Heterozygous HIMP1-Tg-L1 islet cells show an enhanced tolerance to low oxygen or glucose insults. Following similar
procedures described previously [21], primary islet cells of 5-week-old heterozygous L1 or wild-type (Wt) littermate mice were dispersed and cultured
under (A) the hypoxia (5% O2) condition for 15 h or (B) under the low (2.5 mmol/l) or high (11 mmol/l) glucose conditions for 48 h. Viable or dead
cells (via apoptotic and/or necrotic pathways) were examined by trypan blue staining, and the percentages calculated by the procedures described in
the Materials and Methods are shown as mean 6 SD. n=6; *, P,0.05.
doi:10.1371/journal.pone.0034126.g003
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expression level or post-translational modifications of HIF and/or
other involved transcriptionfactorsbetweenpancreatica-a n db-cells.
This possibility needs to be further clarified in follow-up studies.
In summary, our findings provide new insights into the
mechanisms for susceptibilities of b-cells to hypoxia/hypoglycemia
influences such as at the microenvironment within early implanted
islets in transplantation. Also, our findings clearly demonstrate the
sensitivity of basal insulin biosynthesis and secretion to changes in
mitochondria, and show a potential value of HIMP1 overexpres-
sion at relatively low levels in modulating b-cell survival and
function. In diabetes treatments, the potential value of HIMP1
expression ectopically in primary b-cells of transgenic animals may
lie in islet transplantation. Expression of HIMP1, perhaps in
combination with other protective molecules such as antioxidant
enzymes, may be a possible approach to reduce primary b-cell
nonfunction of islet grafts by using nonhuman donor animals such
as transgenic pigs. In addition, to reveal and apply any possible
means to regulating optimal expressions of natural HIMP1 gene in
b-cells will be helpful for protection of b-cells in diabetes
treatments. The mechanisms by which HIMP1 overexpression at
lower levels enhances basal insulin production and b-cell survival
while at toxic higher levels causing b-cell failure and diabetes
deserve further study. HIMP1-Tg mice maintaining in a number
of lines provide an ideal tool for answering these questions.
Materials and Methods
Ethics statement
All animal and tissue sample experiments have been approved
by the Institutional Animal Care and Use Committee of The Ohio
State University (protocol number 2007A0040 and 2010A0024)
and were performed in accordance with the guidelines of the
National Institutes of Health and The Ohio State University.
Generation of HIMP1 transgenic mice
The expression cassette of MIP with a fragment (,2.1 kb) of
human growth hormone gene for stable high-level expression in
pGEM-11Zf vector (Promega, Sunnyvale, CA, USA) was used
[33,34]. Mouse HIMP1-a cDNAs (,0.36 kb) amplified with a set
of primers (59-CTTCTCGAGGCGGCCAGAAACCGGCAG-
GAC-39 and 59-AGTCTCGAGAGCTCTTCTAAGGCTTAGG
GC-39) was inserted into the Xho1 cloning site in the MIP
expression cassette and determined by Sequencing. The con-
structed MIP-HIMP1 expression cassette was injected into the
pronuclei of fertilized oocytes from C57BL/6J mice (The Jackson
Laboratory, Bar Harbor, Maine, USA). Three founders were
obtained and transgenic mice of 3 lines denoted as ‘HIMP1-Tg
L1, L2 and L3’ were produced by breeding of transgenic founders
with C57BL/6J mice. HIMP1-Tg mice were identified by PCR
using genomic DNAs obtained from mice tails as the template.
Figure 4. Heterozygous HIMP1-Tg-L1 mice show an enhanced basal insulin secretion. 5- and 8-week-old heterozygous L1 and wild-type
(Wt) littermate mice were fasted for 15 h and then subjected to IPGTT studies (2 g/kg body weight). Equal numbers of male and female mice were
tested in individual groups. The blood glucose or insulin levels measured in IPGTT studies are shown. The data in (A to D) are presented as the mean
6 SD. n=10; *, P,0.05.
doi:10.1371/journal.pone.0034126.g004
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GGTTGT-39 and 59-CTGGGCTTAGATGGCGATACTCAC-
39) were selected specifically from the MIP-HIMP1 expression
cassette DNA rather than natural HIMP1 gene in the genome of
mouse, a PCR product (364 bp) can be only amplified from HIMP1-
Tg mice. The PCR was performed under the following conditions:
3m i na t9 4 uC; 40 sec at 94uC and 80 secat 68uC for 5 cycles; 40 sec
at 94uC, 30 sec at 57uC, and 80 sec at 72uC for 38 cycles followed by
7m i n a t 7 2 uC. Radioactive primers used were labeled with
[c-
32P]ATP (1.11610
14 Bq/mmol, Perkin Elmer Life Science,
Waltham, MA, USA) as described previously [24].
Measurements of body weight and blood glucose or
insulin levels
Mice maintained in a temperature-controlled room on a 12 h
light-dark cycle were given free access to food and water. Body
weight and blood glucose of HIMP1-Tg and littermate mice were
measured once a week during 4–12 weeks, every two weeks during
14–30 weeks of age, and then measured occasionally afterwards.
Blood samples for glucose and insulin assay were collected from
mouse tail vein. Blood glucose or insulin concentrations were
measured by One Touch Ultra meter (LifeScan, Milpitas, CA,
USA) or Rat Insulin RIA kit (Millipore, Billerica, MA, USA).
Islet isolation and culture
Islets isolation with collagenase (Sigma-Aldrich, St Louis, MO,
USA) digestion and culture with 10% fetal calf serum (FCS)/
RPMI 1640 media (containing 11 mmol/l glucose, Invitrogen,
Carlsbad, CA, USA) were described previously [18,21,24].
Overnight cultured islets were then subjected to treatments/
analyses.
Examination of dead islet cells cultured at different
oxygen/glucose conditions
Equal numbers of islet cells which dispersed by trypsin of 5-
week-old L1 and littermate mice were cultured in 10% FBS/
RPMI 1640 media (containing 11 mmol/l glucose) overnight.
These cells were then subjected to 15 h hypoxia (5% O2)o rt o
48 hour low (2.5 mmol/l) and customary (11 mmol/l) glucose
culture conditions. Viable or dead cells were examined by Trypan
Blue (Invitrogen) staining method [35] and then counted in
haemocytometer chambers. We calculated the percentage of
viable or dead cells in total islet cells at the indicated time points
using the formulas: viable cell (%)=(viable cell number)6100%/
(dead cell number+viable cell number); dead cell (%)=(dead cell
number)6100%/(dead cell number+alive cell number).
Intraperitoneal (i.p) glucose tolerance test (IPGTT)
Mice at the age of 5 and 8 weeks were fasted overnight for 15 h
and then injected i.p. with glucose (2 g/kg body weight). Blood
glucose and insulin levels were determined from tail vein at 0
(before glucose administration), 30, 60 and 120 min after glucose
administration.
Figure 5. Heterozygous HIMP1-Tg-L1 islets show an enhanced basal (pro)insulin biosynthesis. Islets isolated from 5-week-old
heterozygous HIMP1-Tg-L1 or wild-type (Wt) mice were cultured for 15 h at the 2.5 mmol/l glucose condition. Insulin secreted during the 15 h
culture was examined by RIA, and the proportion of secreted insulin in the islet insulin content was shown in (A, lower panel). The proinsulin and
insulin contents of L1 and Wt islets were determined by insulin antisera alone on the same blot membrane, normalized by tubulin, and shown in (B).
(C) The a-cell (determined by glucagon immunoreactivity, green) and b-cell (determined by insulin immunoreactivity, red) area per sectional islet unit
in the pancreatic tissues of 5-week-old L1 heterozygote and wild-type littermate mice was analyzed using ImageJ software. Data in (A to C) were
shown as mean 6 SD. n=6; *, P,0.05. Scale bar in (B), 100 mm.
doi:10.1371/journal.pone.0034126.g005
Effects of Ectopic HIMP1 Overexpression in b-Cells
PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e34126Immunohistochemistry and immunoblot
Double-staining with antibodies against to HIMP1 (1:500) [21],
rat C-peptide 2 (1:500, Millipore), insulin (1:2000, Millipore), and
glucagons (1:2000, Millipore) on pancreatic sections (5 mm
thickness) was performed as described previously [21,24].
Fluorescent images were examined with an Axiovert 200
microscope (Carl Zeiss, Oberkochen, Germany). Pancreas/islet
proteins in tricine sample buffers were resolved by 16.5% tricine-
SDS-PAGE for immunoblot analyses as described previously
[18,24].
Statistical analysis
Densitometry of protein bands in immunoblot images or
densitometry of fluorescent images were quantified by ImageJ
software. Data are shown as mean 6 SD. Statistical significance
(*P,0.05, ** P,0.01) was assessed by two-tailed Student’s t-test or
analysis of variance if appropriate. All experiments were carried
out at least three times.
Supporting Information
Figure S1 Blood glucose concentrations of 5-weeks-old
L1 homozygotes and L2/3 heterozygotes.
(TIF)
Figure S2 The (pro)insulin content and secreted insulin
level of HIMP1-Tg-L1 and control islets after 15 h
culture at the 11 mmol/l glucose condition. Islets isolated
from 5-week-old heterozygous HIMP1-Tg-L1 or wild-type (Wt)
mice were cultured for 15 h at 2.5 mmol/l glucose conditions.
Insulin secreted during the 15 h culture was examined by RIA,
and the proportion of secreted insulin in the islet insulin content
was shown in (A, right panel). The proinsulin and insulin contents
of L1 and Wt islets were determined by insulin antisera alone on
the same blot membrane, normalized by tubulin, and shown in (B).
Data in (A and B) were shown as mean 6 SD. n=6.
(TIF)
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